Received May 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMAB043A | — |
Menveo 2 vial inadvertent liquid portion only administration; Menveo 2 vial inadvertent liquid portion only administration; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Men ACWY-CRM NVS (Menveo) (batch number AMAB043A, expiry date 31-JUL-2025) for prophylaxis. On an unknown date, the patient received Menveo. On an unknown date, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: Menveo 2 vial inadvertent liquid portion only administration) and inappropriate dose of vaccine administered (Verbatim: Menveo 2 vial inadvertent liquid portion only administration). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 21-MAY-2025 The Clinic Supervisor wanted to know the recommendations and the required waiting period if revaccination was necessary after only the liquid portion of Menveo (2-vial) had been administered, which led to Inappropriate preparation of medication and Inappropriate dose of vaccine administered. The health care provider had been unaware of which patient may have received this until they realized, days later, that a few patients had received Menveo. Only the lot number, expiration date, and a possible range of administration dates had been shared. The Vaccine Administration Facility was the same as the Primary Reporter. The suspected vaccine start date was possibly between 12th March 2025, and 29th April 2025.